Home | Welcome to Contract Pharma   
Last Updated Monday, October 20 2014
Print

SCT, OMT In Antibody Development Pact



Published December 3, 2012
Related Searches: Development
Single Cell Technology (SCT) and Open Monoclonal Technology (OMT) have entered a collaboration under which OMT will use its OmniRat transgenic animal platform to generate human antibodies against a therapeutic target identified by SCT. SCT will use its platform to screen plasma cells, measure the kinetics of secreted antibodies, and sequence the cognate light and heavy chain mRNA powered by Next Generation Sequencing (NGS). SCT will advance and partner the program and will have an option to develop and commercialize selected products resulting from the research.
 
Dr. Chun-Nan Chen, founder and chief executive officer of SCT said, “This partnership with OMT will demonstrate the value of delineating the antibody repertoire of the humoral response by NGS early during antibody discovery. The human immune gene sequences engineered into OmniRat by OMT will work perfectly with SCT’s massive screening and sequencing platform. We anticipate exciting results.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On